SEHK:867Pharmaceuticals
China Medical System Wins Desidustat Approval Raising Nephrology Growth Questions
China Medical System Holdings (SEHK:867) has received marketing approval in China for Desidustat Tablets, an oral treatment for renal anaemia in non dialysis chronic kidney disease patients.
The approval adds a new drug to the company’s nephrology portfolio and targets a major unmet medical need in China.
China Medical System Holdings is drawing fresh attention after this new approval, with the share price at HK$13.49 and a 1 year return of 81.4%. The stock has also seen a 6.1% gain over...